Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.

ABSTRACT:

Introduction

Emicizumab promotes effective haemostasis in people with haemophilia A (PwHA). It is indicated for routine prophylaxis of bleeding episodes in PwHA with or without factor (F)VIII inhibitors.

Aim

To investigate the effect of emicizumab dose up-titration in PwHA with suboptimal bleeding control.

Methods

Data from seven completed or ongoing phase III studies were pooled. Pharmacokinetics, pharmacodynamics and bleeding events were evaluated before and after dose up-titration. Adverse events (AEs) were compared between PwHA with and without dose up-titration.

Results

Of 675 PwHA evaluable for the analysis, 24 (3.6%) had their maintenance dose up-titrated to 3 mg/kg once weekly (QW). Two participants had neutralising antibodies (nAbs) associated with dec

SUBMITTER: Schmitt C 

PROVIDER: S-EPMC10091821 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature